JP2001521002A5 - - Google Patents

Download PDF

Info

Publication number
JP2001521002A5
JP2001521002A5 JP2000517723A JP2000517723A JP2001521002A5 JP 2001521002 A5 JP2001521002 A5 JP 2001521002A5 JP 2000517723 A JP2000517723 A JP 2000517723A JP 2000517723 A JP2000517723 A JP 2000517723A JP 2001521002 A5 JP2001521002 A5 JP 2001521002A5
Authority
JP
Japan
Prior art keywords
krebs cycle
cycle intermediate
oxaloacetate
keto
converted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000517723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001521002A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/018120 external-priority patent/WO1999021565A1/en
Publication of JP2001521002A publication Critical patent/JP2001521002A/ja
Publication of JP2001521002A5 publication Critical patent/JP2001521002A5/ja
Withdrawn legal-status Critical Current

Links

JP2000517723A 1997-10-24 1998-09-01 脳の代謝機能不全のための栄養補充剤 Withdrawn JP2001521002A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6316597P 1997-10-24 1997-10-24
US60/063,165 1997-10-24
PCT/US1998/018120 WO1999021565A1 (en) 1997-10-24 1998-09-01 Nutritional supplement for cerebral metabolic insufficiencies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010106232A Division JP2010189432A (ja) 1997-10-24 2010-05-06 脳の代謝機能不全のための栄養補充剤

Publications (2)

Publication Number Publication Date
JP2001521002A JP2001521002A (ja) 2001-11-06
JP2001521002A5 true JP2001521002A5 (enExample) 2010-01-21

Family

ID=22047375

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000517723A Withdrawn JP2001521002A (ja) 1997-10-24 1998-09-01 脳の代謝機能不全のための栄養補充剤
JP2010106232A Pending JP2010189432A (ja) 1997-10-24 2010-05-06 脳の代謝機能不全のための栄養補充剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010106232A Pending JP2010189432A (ja) 1997-10-24 2010-05-06 脳の代謝機能不全のための栄養補充剤

Country Status (7)

Country Link
US (2) US6537969B1 (enExample)
EP (1) EP1032403B1 (enExample)
JP (2) JP2001521002A (enExample)
AT (1) ATE555780T1 (enExample)
AU (1) AU760140B2 (enExample)
CA (1) CA2306875C (enExample)
WO (1) WO1999021565A1 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535104T2 (de) * 1994-11-08 2007-02-08 Avicena Group, Inc., Cambridge Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose
US20050245612A1 (en) * 2004-05-03 2005-11-03 Blass John P Pharmaceutical compositions for metabolic insufficiencies
US20060128671A1 (en) * 1998-04-02 2006-06-15 The General Hospital Corporation Compositions containing a combination of a creatine compound and a second agent
AU759467B2 (en) * 1998-04-02 2003-04-17 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE19932197A1 (de) * 1999-07-09 2001-01-18 Neudecker Birgit Topisch anzuwendendes Mittel mit schützender und regenerativer Wirkung
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US7208180B2 (en) 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
RS52083B (sr) 2001-01-12 2012-06-30 Fumapharm Ag Amidi fumarne kiseline
BR0203902A (pt) 2001-02-14 2003-01-28 Matthias Rath Composições de compostos bioquìmicos envolvidos no metabolismo bioenergético das células e método de uso da mesma
US20060057107A1 (en) * 2001-12-21 2006-03-16 Shaked Ze Ev Combination treatment for multiple sclerosis
EP1475090A4 (en) * 2002-02-14 2007-08-08 Ajinomoto Kk DRUG AGAINST MITOCHONDRIAL DISEASES
EP1820806A1 (en) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
EP1567180A4 (en) * 2002-06-04 2010-03-10 Avicena Group Inc METHODS OF TREATING COGNITIVE DYSFUNCTIONS BY MODULATING BRAIN ENERGY METABOLISM
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1524989B1 (en) 2002-08-01 2013-11-06 Yeda Research And Development Co., Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
JP2006503847A (ja) * 2002-09-27 2006-02-02 チルドレンズ メディカル センター コーポレーション 神経疾患の治療のための方法および組成物
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
SE0301947D0 (sv) * 2003-07-01 2003-07-01 Gramineer Internat Ab New method and uses
JP2007530417A (ja) * 2003-07-01 2007-11-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞及び生物の寿命及びストレス応答を操作するための組成物
BRPI0412118A (pt) * 2003-07-01 2006-08-15 Essentys Ab métodos para melhorar a absorção de aminoácidos, para reduzir a absorção da glicose plasmática, e para prevenir, inibir ou aliviar uma condição de elevado teor de glicose em um vertebrado, e, uso de akg, derivados ou metabólitos de akg, análogos de akg, ou misturas destes
ATE380027T1 (de) 2003-09-09 2007-12-15 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
CN101247793B (zh) 2003-12-29 2013-04-10 哈佛大学校长及研究员协会 治疗或预防肥胖和胰岛素抗性病症的组合物
JP2008503479A (ja) * 2004-06-16 2008-02-07 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Ｂａｘ媒介性アポトーシスを調節する方法及び組成物
PL368572A1 (en) * 2004-06-17 2005-12-27 Sgp & Sons Ab Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections
WO2006004722A2 (en) * 2004-06-30 2006-01-12 Biomol Research Laboratories, Inc. Compositions and methods for selectively activating human sirtuins
US20060024385A1 (en) * 2004-07-27 2006-02-02 Pedersen Mark A Metabolic capacity enhancing compositions and methods for use in a mammal
PL369552A1 (pl) * 2004-08-12 2006-02-20 Sgp & Sons Ab Preparat farmaceutyczny lub/i żywieniowy lub/i laboratoryjny wzmagający, wspomagający funkcjonowanie komórek nerwowych i układu nerwowego oraz zastosowanie preparatu farmaceutycznego lub/i żywieniowego w procesie ochrony funkcji układu nerwowego oraz zastosowanie preparatu do ochrony wzrostu stymulacji namnażania i zapobiegania apoptozie komórek nerwowych
RU2007111720A (ru) * 2004-08-30 2008-10-10 Канека Корпорейшн (Jp) Активаторы митохондрий
CA2589995C (en) * 2004-12-17 2016-01-05 Alan B. Cash Oxaloacetate, oxaloacetic acid, and oxaloacetate salts for treating cancer
EP1841445A4 (en) * 2004-12-21 2010-06-02 Critical Care Connections Inc THERAPEUTIC NUTRIENT COMPOSITIONS OR COMBINATIONS AND METHODS OF USE
EP1850840A2 (en) * 2005-01-13 2007-11-07 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
BRPI0612923A2 (pt) * 2005-04-28 2010-12-07 Unilever Nv uso do tripeptìdeo map, uso do tripeptìdeo map em combinação com o tripeptìdeo itp e produto alimentìcio
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
AU2006267176A1 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
EP1906995A2 (en) * 2005-07-13 2008-04-09 Crossbeta Biosciences B.V. Adjuvation through cross- structure
JP2007023010A (ja) * 2005-07-19 2007-02-01 Toshiro Azegami 閉経後のホルモンバランス調整及びパーキンソン症の予防改善目的の経口組成物
DE102005035917A1 (de) * 2005-07-28 2007-02-01 November Ag Verwendung von Isocitrat, Isocitronensäure oder einem Derivat davon zur Herstellung eines Medikaments
SI1909600T1 (sl) * 2005-07-29 2012-07-31 Tima Foundation Zmes za nadzor metabolizma alkohola in za zmanjšanje nevarnosti z alkoholom induciranih bolezni
EP2468272A1 (en) * 2006-05-11 2012-06-27 Avicena Group, Inc. Methods of treating a neurological disorder with creatine monohydrate
US8435547B2 (en) * 2006-08-30 2013-05-07 John P. Blass Cream for stimulating mitochondrial activity in the skin
ES2916604T1 (es) 2007-02-08 2022-07-04 Biogen Ma Inc Ensayos de detección de nrf2 y métodos y composiciones relacionados
WO2008096271A2 (en) * 2007-02-08 2008-08-14 Ralf Gold Neuroprotection in demyelinating diseases
EP2058001A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells
US20090269796A1 (en) * 2007-12-05 2009-10-29 The General Hospital Corporation Methods of detecting and treating myocardial ischemia and myocardial infarction
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
US9233099B2 (en) 2012-01-11 2016-01-12 University Of Cincinnati Methods of treating cognitive dysfunction by modulating brain energy metabolism
DK3398594T3 (da) 2012-09-19 2024-09-23 Grespo Ab Sammensætninger til forbedring af hjernefunktion
US20140243400A1 (en) * 2013-02-28 2014-08-28 University of Alaska Anchorage Compositions comprising citric acid and malic acid and methods and uses thereof
WO2014160423A1 (en) 2013-03-13 2014-10-02 Genetic Disease Investigators, LLC Methods and compositions for correction of organ dysfunction
US10238673B2 (en) 2013-03-13 2019-03-26 Genetic Disease Investigators, LLC Methods and compositions for treatment of dry eye and correction of organ dysfunctions
GB201411937D0 (en) * 2014-07-03 2014-08-20 Medical Res Council Succinate dehydrogenase inhibitors (SDH's)
JP6831558B2 (ja) * 2016-08-23 2021-02-17 株式会社Ｈｂｃフナト 脳機能改善組成物
CA3037235A1 (en) * 2016-09-22 2018-03-29 Alan B. Cash Method to alleviate the symptoms of pms
JP6129395B1 (ja) * 2016-10-29 2017-05-17 誠一 荒木 ミトコンドリア活性化に起因した血管内皮細胞保護回復用還元型ビタミンｂ２製剤
IT201700087359A1 (it) * 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201800006725A1 (it) * 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
EP3863624A4 (en) * 2018-10-11 2022-08-31 Imbria Pharmaceuticals, Inc. INTERMEDIATE PRODUCTS FOR TCA CYCLE AND METHODS OF USE
EP3870184A4 (en) * 2018-10-24 2022-07-20 Ponce de Leon Health Designated Activity Company Nicotinamide riboside compositions for healthspan extension
IT202000000442A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
CN118976034A (zh) * 2021-02-05 2024-11-19 沈阳糖化药物研究有限公司 一种用于动物模型中诱导癌症的组合物及其用途
CN115212195B (zh) * 2022-06-17 2024-02-27 重庆医科大学 苹果酸在制备预防和/或治疗抑郁症的药物中的用途
US20250221952A1 (en) * 2025-03-14 2025-07-10 Louis Dischler Methods and compositions for large modifications of atp output by inner mitochondrial membrane latching

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963579A (en) * 1973-10-17 1976-06-15 Sanraku-Ocean Co., Ltd. Microbiological process for the production of pepstatins
US4089985A (en) * 1974-11-11 1978-05-16 Wolff H Ezra Papaya juice product and process
DE2502735B2 (de) * 1975-01-23 1978-11-23 J. Pfrimmer & Co, 8520 Erlangen Verwendung von Glycerophosphaten
BE867467A (fr) * 1977-04-11 1978-11-27 Dow Chemical Co Aliments pour animaux contenant de l'acide malique ou un sel de ce dernier
US4975217A (en) * 1981-07-20 1990-12-04 Kimberly-Clark Corporation Virucidal composition, the method of use and the product therefor
US5185161A (en) * 1984-03-21 1993-02-09 Alcide Corporation Disinfection method and composition therefor
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
GB8617482D0 (en) * 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
US5210083A (en) * 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
EP0331620B1 (de) 1988-03-01 1993-08-11 Birkmayer, Walther, Prof. Dr. Mittel zur Behandlung des Parkinson-Syndroms
AT397201B (de) 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels
ATE107643T1 (de) * 1989-05-05 1994-07-15 Asta Medica Ag Salze des azelastins mit verbesserter löslichkeit.
US5188861A (en) * 1990-05-31 1993-02-23 Royal Domaine Inc. Process for preparing a dried fruit product
US5380721A (en) * 1990-09-10 1995-01-10 Sterling Winthrop Inc. Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
GB9215746D0 (en) 1992-07-24 1992-09-09 Hultman Eric A method of increasing creatine supply depot
FR2709982B1 (fr) * 1993-09-15 1995-12-08 Oreal Emulsions acides stables de type huile-dans-eau et compositions les contenant.
JP3645580B2 (ja) 1993-10-22 2005-05-11 株式会社フジモト・ブラザーズ グルコースエステル誘導体を含有する脳代謝改善剤
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
CN1091604C (zh) * 1995-06-07 2002-10-02 第一制糖株式会社 具有提高了药理作用的加工人参提取物及其制备方法
KR100192678B1 (ko) * 1995-06-07 1999-06-15 손경식 약효가 증강된 가공인삼 제품
ES2162319T3 (es) * 1996-08-13 2001-12-16 Gerolymatos P N Sa Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
US20050245612A1 (en) * 2004-05-03 2005-11-03 Blass John P Pharmaceutical compositions for metabolic insufficiencies
FR2777186B1 (fr) * 1998-04-10 2001-03-09 Oreal Utilisation d'au moins un hydroxystilbene dans une composition raffermissante

Similar Documents

Publication Publication Date Title
JP2001521002A5 (enExample)
US5750572A (en) Salts of a polyunsaturated fatty acid and pharmaceutical formulations containing them
RU2128160C1 (ru) Трометаминная соль (+)-(s)-2-(3-бензоилфенил)пропионовой кислоты, способ ее получения, фармацевтическая композиция
ES2469849T3 (es) Derivados deuterados de isoindolin-1,3-diona como inhibidores de PDE4 y TNF-alfa
US5354885A (en) Process for preparing ethyl ester of L-DOPA
JPS62190160A (ja) （−）−ベンツヒドリルスルフイニルアセトアミド及びその製法
HUT48196A (en) Process for producing benzocycloheptene derivatives and pharmaceuticals comprising such active ingredient
CA2031714A1 (en) R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
AU4950096A (en) Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
ATE118216T1 (de) Dopamin-medikament-vorstufe.
US5863939A (en) Creatine ascorbates and a method of producing them
EP0154756A1 (fr) Citrate de vinpocetine et son procédé de préparation
JPS62502749A (ja) パラメトキシ桂皮酸及びウロカニン酸のアミド、それらの製造法、それらのソ−ラ−フイルタ−としての用途及びそれらを含有する皮膚−薬理的及び化粧用組成物
WO2000002850A3 (de) Sulfonylamino-carbonsäure-n-arylamide als guanylatcyclase-aktivatoren
JPH0322993A (ja) 水溶性ｌ−チロシン誘導体およびｌ−チロシン誘導体の製造方法
DE60018194T2 (de) Hydroxamsäurederivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven wirkstoff enthalten
EP0328634A1 (en) Pharmaceutical compositions for the treatment of psoriasis
TWI356821B (en) Anti-inflammatory agents
WO1999011625A1 (en) Huperzine a derivatives
US5227513A (en) Acetylsalicyloyl-L-carnitine and process for its production
US20220000814A1 (en) Methods for treatment of prader-willi syndrome
US20040176449A1 (en) Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use.
RU2593203C2 (ru) Пантенола докозагексаеноат и его применение для лечения и предупреждения сердечно-сосудистых заболеваний
CA2385301A1 (en) Peeling composition
KR100764155B1 (ko) 타우린 클로라이드와의 ｌ-카르니틴 및 알카노일 ｌ-카르니틴의 비 흡습성 염을 함유하는 경구 투여에 적합한 고형 조성물